Come assumere Maviret?

Come assumere Maviret?

La dose raccomandata di Maviret è 300 mg/120 mg (tre compresse da 100 mg/40 mg), assunte per via orale, una volta al giorno nello stesso momento con del cibo (vedere paragrafo 5.2).

A cosa serve Maviret?

Maviret è un medicinale antivirale usato per il trattamento di adulti e bambini a partire dai 3 anni di età con epatite C cronica (di lungo decorso), una malattia infettiva, causata dal virus dell'epatite C, che colpisce il fegato. Maviret contiene i principi attivi glecaprevir e pibrentasvir.

Quanto costa Epclusa?

Il farmaco, come riportato in Gazzetta, ha un prezzo ex factory (prezzo ricavi industria) di 16.66,67 euro e di 27.506,67 (iva compresa) al pubblico.

Come guarire da HCV?

I farmaci innovativi sinora approvati per la cura dell'epatite C sono:

1. Sofosbuvir.
2. Simeprevir.
3. Daclatasvir.
4. Ledispavir + Sofosbuvir.
5. Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir.
6. Gazoprevir/elbasvir.
7. Sofosbuvir/velpatasvir.
8. Glecaprevir/pibrentasvir.

What is Maviret and what is it for?

• What is Maviret and what is it used for? Maviret is an antiviral medicine used to treat adults with chronic (long-term) hepatitis C, an infectious disease that affects the liver, which is caused by the hepatitis C virus. Maviret contains the active substances glecaprevir and pibrentasvir.

What are the contraindications for Maviret?

• Maviret is not recommended in patients with moderate hepatic impairment (Child-Pugh B) and is contraindicated in patients with severe hepatic impairment (Child-Pugh C) (see sections 4.2, 4.3, and 5.2).

What is magmaviret used to treat?

• MAVIRET is a tablet that contains two active substances called glecaprevir and pibrentasvir. This medicine is used to treat chronic (long-lasting) hepatitis C virus (HCV) infection in adult patients. This medicine belongs to a group of medicines called direct-acting antiviral agents.

Is Maviret safe for patients with compensated liver disease?

• The safety assessment of Maviret in subjects treated for 8, 12 or 16 weeks with compensated liver disease (with or without cirrhosis) was based on registrational Phase 2 and 3 studies which evaluated approximately 2,300 subjects. The most commonly reported adverse reactions (incidence ≥ 10%) were headache and fatigue.